Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3484-3491

  Shinkai, Noboru ^a   Matsuura, Kentaro ^a   Sugauchi, Fuminaka ^a   Watanabe, Tsunamasa ^a   Murakami, Shuko ^a   Iio, Etsuko ^a   Ogawa, Shintaro ^a   Nojiri, Shunsuke ^a   Joh, Takashi ^a   Tanaka, Yasuhito ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MONOCLONAL ANTIBODY; TENOFOVIR; VIRUS DNA;

ADULT; ANALYTICAL EQUIPMENT; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CHEMILUMINESCENT ENZYME IMMUNOASSAY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY AUTOMATION; LIMIT OF DETECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; VIRUS CARRIER; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; ANTIVIRAL AGENTS; AUTOMATION, LABORATORY; CLINICAL LABORATORY TECHNIQUES; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 84886557418     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00726-13     Document Type: Article

References (33)

1. Pan CQ, Zhang JX.2005.Natural history and clinical consequences of hepatitis B virus infection.Int.J.Med.Sci.2:36-40.
2. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S.2005.Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.J.Med.Virol.75:235-239.
3. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ.2007.Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.Clin.Gastroenterol.Hepatol.5: 1462-1468.
4. Werle B, Cinquin K, Marcellin P, Pol S, Maynard M, Trépo C, Zoulim F.2004.Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.J.Viral Hepat.11:74-83.
5. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J.2006.Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.Hepatology 44:675-684.
6. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.2009.Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.Hepatology 49:1141-1150.
7. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN.2004.Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers.Eur.J.Gastroenterol.Hepatol.16:1213- 1218.
8. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, Iinuma K, Mushahwar IK.2004.Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.J. Virol. Methods 115:217-222.
9. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, Giuily N, Castelnau C, Pouteau M, Stern C, Aupérin A, Bedossa P, Asselah T, Marcellin P.2009.Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin.Antivir.Ther. 14:501-511.
10. Matsubara N, Kusano O, Sugamata Y, Itoh T, Mizuii M, Tanaka J, Yoshizawa H.2009.A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection.Transfusion 49:585-595.
11. Shinkai N, Tanaka Y, Matsuura K, Kani S, Naganuma H, Mizokami M.2010.Evaluation and application of a newly developed highly sensitive HBsAg chemiluminescent enzyme immunoassay for chronic hepatitis B patients.Rinsho Byori 58:1078-1084.(Article in Japanese.)
12. Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, Maki N.2002.Sensitive enzyme immunoassay for hepatitis B virus corerelated antigens and their correlation to virus load.J. Clin. Microbiol.40:439-445.
13. Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF.2007.Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.J. Clin. Microbiol.45:3942-3947.
14. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P.2009.High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.J.Hepatol.50:1084-1092.
15. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL.2004.Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.Hepatology 39:804-810.
16. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE.2010.Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus.Hepatology 51:1531-1537.
17. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL.2008.HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.Gastroenterology 135:1192-1199.
18. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H.2009.Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.J.Med.Virol.81:27-33.
19. Shinkai N, Tanaka Y, Orito E, Ito K, Ohno T, Hirashima N, Hasegawa I, Sugauchi F, Ueda R, Mizokami M.2006.Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection.Hepatol Res.36:272-276.
20. Hollinger FB.2008.Hepatitis B virus infection and transfusion medicine: science and the occult.Transfusion 48:1001-1026.
21. Raimondo G, Pollicino T, Cacciola I, Squadrito G.2007.Occult hepatitis B virus infection.J.Hepatol.46:160-170.
22. van Hemert FJ, Zaaijer HL, Berkhout B, Lukashov VV.2008.Occult hepatitis B infection: an evolutionary scenario.Virol.J.5:146.doi:10.1186/1743-422X-5-146.
23. Dettori S, Candido A, Kondili LA, Chionne P, Taffon S, Genovese D, Iudicone P, Miceli M, Rapicetta M.2009.Identification of low HBVDNA levels by nucleic acid amplification test (NAT) in blood donors.J.Infect.59:128-133.
24. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K.2007.Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.Transfusion 47:1197-1205.
25. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E.2009.Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier.Ann.Oncol.20:2013-2017.
26. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM.2005.Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibodypositive patient: potential implications for future prophylaxis recommendations.Leuk.Lymphoma 46:1085-1089.
27. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY.2010.Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.Ann.Hematol.89:255-262.
28. Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.2009.Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.J.Clin.Gastroenterol.43:496-498.
29. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.2009.Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.J.Clin.Oncol.27:605-611.
30. Chen WN, Oon CJ.2000.Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high antihepatitis B virus antibody levels but negative for HBsAg.J. Clin. Microbiol.38:2793-2794.
31. Wu C, Deng W, Deng L, Cao L, Qin B, Li S, Wang Y, Pei R, Yang D, Lu M, Chen X.2012.Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance.J. Virol.86:4658-4669.
32. Oon CJ, Chen WN, Goh KT, Mesenas S, Ng HS, Chiang G, Tan C, Koh S, Teng SW, Toh I, Moh MC, Goo KS, Tan K, Leong AL, Tan GS.2002.Molecular characterization of hepatitis B virus surface antigen mutants in Singapore patients with hepatocellular carcinoma and hepatitis B virus carriers negative for HBsAg but positive for anti-HBs and anti-HBc.J.Gastroenterol.Hepatol. 17(Suppl):S491-S496.
33. Coleman PF.2006.Detecting hepatitis B surface antigen mutants.Emerg. Infect. Dis.12:198-203.